Clinical Trials · NCT04440345
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 60
- Start date
- Jun 2020
- Locations
- 1 site, China
- Primary endpoint
- Number of treatment adverse events